DelveInsight’s, “Myelofibrosis Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Myelofibrosis Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

Key Takeaways from the Myelofibrosis Pipeline Report

• On June 04, 2026, Novartis Pharmaceuticals initiated a phase 3 trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
• On June 02, 2026, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. highlighted a Phase II Clinical Trial of TQ05105 Tablets Versus Hydroxyurea Tablets in the Treatment of Moderate and High Risk Myelofibrosis.
• DelveInsight’s Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
• The leading Myelofibrosis Companies such as PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
• Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.

Access DelveInsight’s in-depth Myelofibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Myelofibrosis Clinical Trials and Studies

Myelofibrosis Overview

Myelofibrosis is a chronic blood cancer in which clonal abnormalities in hematopoietic stem cells drive progressive bone marrow fibrosis, resulting in ineffective blood cell production and clinical features such as anemia, splenomegaly, and fatigue. It is classified as a BCR-ABL1–negative myeloproliferative neoplasm and may arise de novo or evolve from antecedent conditions like polycythemia vera or essential thrombocythemia. The disease is strongly associated with driver mutations in JAK2, CALR, or MPL, which lead to persistent activation of the JAK-STAT signaling pathway and a pro-inflammatory cytokine milieu.

Myelofibrosis Emerging Drugs

• Ropeginterferon alfa-2b: PharmaEssentia Corporation

Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon designed for sustained activation of interferon signaling with improved tolerability and convenient dosing compared to earlier interferons. It exerts antiproliferative and immunomodulatory effects, helping to suppress malignant hematopoietic clones and restore more normal bone marrow function. The drug is currently being studied in a Phase III clinical trial for the treatment of Myelofibrosis.

• Roginolisib: iOnctura

Roginolisib is an orally available, first-in-class allosteric modulator of PI3Kδ, distinguished by its unique binding mode that alters the protein’s 3D conformation and selectively inhibits its activity. By targeting the PI3Kδ isoform commonly dysregulated in cancers and expressed in immunosuppressive cells, it aims to reverse tumor-associated immune suppression while directly inhibing malignant cell proliferation. In myelofibrosis, Roginolisib may help counteract immune-mediated resistance mechanisms that limit current therapies. It is currently being evaluated in a Phase II clinical trial for the treatment of Myelofibrosis.

• RVU120: Ryvu Therapeutics

RVU120 is an oral, selective inhibitor of CDK8 and CDK19, key regulators of transcriptional pathways involved in oncogenesis and inflammation. In Myelofibrosis, it modulates aberrant signaling such as STAT-driven pathways, helping to suppress malignant hematopoietic cell proliferation. The drug has demonstrated potential disease-modifying activity, including reduction of inflammatory cytokines and fibrosis-associated signaling. RVU120 is currently in Phase II of its clinical development, with early studies indicating activity in patients resistant or refractory to JAK inhibitor therapies.

• PRT12396: Prelude Therapeutics

PRT12396 is a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). It has received Investigational New Drug (IND) clearance from the US Food and Drug Administration, enabling clinical evaluation in advanced malignancies, including hematologic cancers. It is currently being evaluated in a Phase I clinical trial for the treatment of Myelofibrosis.

The Myelofibrosis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
• Myelofibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

Explore DelveInsight’s expert-driven report today! @ Myelofibrosis Unmet Needs

Myelofibrosis Companies

PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myelofibrosis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Myelofibrosis Therapies @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Myelofibrosis Pipeline Report

• Coverage- Global
• Myelofibrosis Companies- PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
• Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
• Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Myelofibrosis Pipeline Report @ Myelofibrosis Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Myelofibrosis: Overview
4. Myelofibrosis Pipeline Therapeutics
5. Myelofibrosis Therapeutic Assessment
6. Myelofibrosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ropeginterferon alfa-2b: PharmaEssentia Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Roginolisib: iOnctura
12. Drug profiles in the detailed report…..
13. PRT12396: Prelude Therapeutics
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Myelofibrosis Key Companies
20. Myelofibrosis Key Products
21. Myelofibrosis- Unmet Needs
22. Myelofibrosis- Market Drivers and Barriers
23. Myelofibrosis- Future Perspectives and Conclusion
24. Myelofibrosis Analyst Views
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight